EQ Equillium, Inc.

EQ financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1746466 Exchange: Nasdaq SIC: 2834 (Pharmaceutical Preparations)
Showing 3 of 8 annual and 0 of 34 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Non-accelerated filer<br>Smaller reporting company
Entity Type
Operating
Public Float
$7.10M (Jun 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Incorporated
DE
Fiscal Year End
December (1231)
Phone
(858) 412-5302
EIN
821554746
Headquarters
LA JOLLA, CA, 92037
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.

▼ Key Metrics (TTM)

As of Jun 30, 2026
Financials
Revenue
-
Net Income
$-18.01M
Total Assets
$58.67M
Total Equity
$56.02M
Total Debt
-
Free Cash Flow
$-20.09M
Ratios
Return on Equity
-32.1%
Return on Assets
-30.7%
Current Ratio
23.4x
FCF / Assets
-34.2%

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

In fiscal 2025, Equillium, Inc. reported net loss of $22.40M. The company reported diluted EPS of -$0.39, adding a shareholder-level measure to the absolute income figures considered below. Diluted shares averaged 57.30M; this is the reported share base over which the company’s diluted per-share earnings were spread. Compared with 35.36M diluted shares in fiscal 2024, the current 57.30M base was 62.1% higher. At period end, total assets were $31.89M, framing the scale of the company’s operating and financing commitments.

Profitability

The reported operating result was an operating loss of $23.63M, reflecting costs that exceeded gross profit. The company ended the period with a net loss of $22.40M, extending the operating result through all remaining items. EBITDA was negative $23.52M, showing a deficit before interest, taxes, depreciation, and amortization. The company reported a pretax loss of $22.40M, before the effect of income taxes. The company recognized $0.00 of income tax for the period, completing the transition from pretax income to net income. The loss-to-equity relationship was 78.3%, placing the bottom-line deficit against shareholder capital. The net loss equaled 70.2% of period-end assets, showing the deficit relative to the asset base. The bottom-line deficit increased from $8.07M in fiscal 2024 to $22.40M.

Liquidity and Capital Structure

At period end, the $31.89M asset base was financed through $3.29M of liabilities and $28.60M of equity. At period end, current assets of $31.04M compared with current liabilities of $2.93M, defining the company’s short-term resource position. Current assets covered current liabilities by 10.58x, leaving a positive buffer for near-term obligations. Reported cash and equivalents were $30.28M, separating immediately recognizable cash resources from the rest of the current-asset base. The equity-to-assets relationship was 89.7%, placing book capital against the total resource base. Relative to total assets, liabilities measured 10.3%, complementing the separate equity-based view of the company’s capital structure. Measured against total assets, cash and equivalents represented 95.0%, a balance-sheet composition measure rather than a liquidity forecast. The asset base changed 24.5% from $25.60M in fiscal 2024, leaving current total assets higher year over year. Against $19.06M of equity in fiscal 2024, the current book-equity balance moved 50.0% and ended higher. Compared with $18.09M in fiscal 2024, the current cash balance moved 67.4% and finished higher.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $22.75M, rather than cash generation from operations. Capital expenditures used $48.00K in addition to the operating cash outflow, increasing the total cash consumed by operations and investment during the period. Operating cash flow and capital spending combined to leave a $22.79M cash deficit after capital spending. Relative to total assets, the post-investment cash deficit measured 71.5%. Compared with a $19.03M operating cash outflow in fiscal 2024, the current outflow increased to $22.75M.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual (FY)
Quarterly 🔒
Chart 🔒
Annual financial statements for Equillium, Inc.
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
Revenue - $41.10M $36.08M
OPERATING EXPENSES
R&D Expense $12.84M $37.43M $37.04M
SG&A Expense $10.79M $11.94M $13.57M
Operating Income $-23.63M $-8.27M $-14.52M
NON-OPERATING INCOME / EXPENSE
Interest Expense - - $491.00K
Interest Income $833.00K $1.38M $2.33M
Other Income/Expense - - $-76.00K
Pretax Income $-22.40M $-7.71M $-12.76M
Income Tax $0 $361.00K $580.00K
Net Income $-22.40M $-8.07M $-13.34M
PER SHARE & SUPPLEMENTAL
Diluted EPS $-0.39 $-0.23 $-0.38
Diluted Shares 57.30M 35.36M 34.73M
EBITDA $-23.52M $-8.13M $-14.40M
Depreciation & Amortization $116.00K $137.00K $126.00K
Balance Sheet
ASSETS
Cash & Equivalents $30.28M $18.09M $23.22M
Short-term Investments - $4.49M $17.65M
Accounts Receivable - $0 $3.74M
Other Current Assets $214.00K $429.00K $235.00K
Current Assets $31.04M $24.98M $49.35M
PP&E (Net) $164.00K $262.00K $315.00K
Other Noncurrent Assets $27.00K - $70.00K
Noncurrent Assets $849.00K $626.00K $1.18M
Total Assets $31.89M $25.60M $50.53M
LIABILITIES
Accounts Payable $755.00K $2.68M $4.71M
Other Current Liabilities $213.00K $303.00K $431.00K
Current Liabilities $2.93M $6.36M $27.57M
Noncurrent Liabilities $356.00K $187.00K $384.00K
Total Liabilities $3.29M $6.54M $27.96M
EQUITY
Common Stock $5.00K $3.00K $3.00K
Additional Paid-in Capital $244.43M $212.08M $208.17M
Retained Earnings $-216.21M $-193.81M $-185.74M
Accumulated OCI $363.00K $781.00K $140.00K
Total Equity $28.60M $19.06M $22.57M
Total Liabilities & Equity $31.89M $25.60M $50.53M
SUPPLEMENTAL
Shares Outstanding 61.46M 35.56M 35.25M
Check: A − (L + E + NCI) - - -
Cash Flow Statement
Cash from Operations $-22.75M $-19.03M $-21.78M
Capital Expenditures $48.00K $85.00K $50.00K
Cash from Investing $4.46M $13.81M $-4.76M
Cash from Financing $30.43M $164.00K $-9.23M
Free Cash Flow $-22.79M $-19.11M $-21.83M
Beginning Cash (CFS) $18.09M $23.22M -
Net Change in Cash $12.15M $-5.05M -
Effect of FX on Cash $47.00K $-83.00K $-118.00K
Calculated Ending Cash $30.28M $18.09M -
Cash per BS $30.28M $18.09M $23.22M
Cash scope difference (CFS − BS) - - -
Cash per CFS $30.28M $18.09M $23.22M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

Is Equillium, Inc. profitable?

No. Equillium, Inc. reported $-18.01M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.

Does Equillium, Inc. generate free cash flow?

No. Free cash flow was $-20.09M for trailing twelve months. Operating cash flow was $-19.97M.